Sensitive amplified luminescent proximity homogeneous assay for the quantitative detection of CA242.

[1]  Hongliang Liang,et al.  Correlation of Serum CA242, CA724, and TPA Levels with Clinicopathological Features and Prognosis in Patients with Inflammatory Bowel Disease Complicated with Rectal Cancer , 2022, Journal of oncology.

[2]  Zhenqi Zhang,et al.  Association of multiple tumor markers with newly diagnosed gastric cancer patients: a retrospective study , 2022, PeerJ.

[3]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[4]  A. Stoita,et al.  Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? , 2021, World journal of gastroenterology.

[5]  Shaoqiang Wu,et al.  Application of an AlphaLISA method for rapid sensitive detection of African swine fever virus in porcine serum , 2021, Applied Microbiology and Biotechnology.

[6]  I. Endo,et al.  Liver metastases , 2021, Nature Reviews Disease Primers.

[7]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[8]  Shenxia Gao,et al.  Development of a Novel Homogeneous Nanoparticle-Based Assay for Rapid and High-Throughput Quantitation of the sST2 Protein in Human Serum , 2020, International journal of nanomedicine.

[9]  J. Valle,et al.  Pancreatic cancer , 2020, The Lancet.

[10]  Bo Li,et al.  Clinical significance and diagnostic value of serum NSE, CEA, CA19-9, CA125 and CA242 levels in colorectal cancer , 2020, Oncology letters.

[11]  Walter G. Park,et al.  Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium , 2019, Gut.

[12]  T. Donahue,et al.  Pancreatic Cancer. , 2019, JAMA.

[13]  Min Liu,et al.  A Label-Free Electrochemical Immunosensor for Detection of the Tumor Marker CA242 Based on Reduced Graphene Oxide-Gold-Palladium Nanocomposite , 2019, Nanomaterials.

[14]  M. Alkady,et al.  Diagnostic and prognostic value of serum IL-23 in colorectal cancer. , 2019, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.

[15]  Eugene J Koay,et al.  Early Detection of Pancreatic Cancer: Opportunities and Challenges. , 2019, Gastroenterology.

[16]  Bas Groot Koerkamp,et al.  International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer , 2018, JAMA surgery.

[17]  Cheryl M. Armstrong,et al.  Detection of Shiga Toxin 2 Produced by Escherichia coli in Foods Using a Novel AlphaLISA , 2018, Toxins.

[18]  P. Li,et al.  Establishment of a novel homogeneous nanoparticle-based assay for sensitive procalcitonin detection of ultra low-volume serum samples , 2018, International journal of nanomedicine.

[19]  Bruce D Hammock,et al.  Noncompetitive Homogeneous Detection of Small Molecules Using Synthetic Nanopeptamer-Based Luminescent Oxygen Channeling. , 2018, Analytical chemistry.

[20]  Ludmila V. Danilova,et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.

[21]  L. Ruilope,et al.  Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9–Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA , 2017, Front. Immunol..

[22]  Zhanfang Ma,et al.  Multiple signal amplification strategies for ultrasensitive label-free electrochemical immunoassay for carbohydrate antigen 24-2 based on redox hydrogel. , 2017, Biosensors & bioelectronics.

[23]  M. Sierzega,et al.  Semiquantitative immunohistochemistry for mucin (MUC1, MUC2, MUC3, MUC4, MUC5AC, and MUC6) profiling of pancreatic ductal cell adenocarcinoma improves diagnostic and prognostic performance , 2016, Histopathology.

[24]  Rong-Liang Liang,et al.  Rapid quantitation of human epididymis protein 4 in human serum by amplified luminescent proximity homogeneous immunoassay (AlphaLISA). , 2016, Journal of immunological methods.

[25]  Xiao-qin Xu,et al.  Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[26]  Z. Dong,et al.  Development of an amplified luminescent proximity homogeneous assay for quantitative determination of hepatitis B surface antigen in human serum. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[27]  A. Mechaly,et al.  A novel homogeneous immunoassay for anthrax detection based on the AlphaLISA method: detection of B. anthracis spores and protective antigen (PA) in complex samples , 2013, Analytical and Bioanalytical Chemistry.

[28]  U. Ballehaninna,et al.  Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review , 2011, Indian journal of surgical oncology.

[29]  M. Duffy,et al.  Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Y. Tian,et al.  The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[31]  U. Manne,et al.  MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine‐needle aspiration , 2003, Cancer.

[32]  S. Kawa,et al.  Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. , 1994, British Journal of Cancer.

[33]  O. Nilsson,et al.  Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins. , 1991, The Journal of biological chemistry.

[34]  S. Nordling,et al.  Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. , 1989, British Journal of Cancer.

[35]  H. Biao,et al.  Clinical significance in combined detection of serum pepsinogen I, pepsinogen II and carbohydrate antigen 242 in gastric cancer. , 2014, Hepato-gastroenterology.

[36]  N. Bardeesy,et al.  Pancreatic adenocarcinoma. , 2014, The New England journal of medicine.

[37]  N. Kohno,et al.  Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors. , 2004, International journal of oncology.